Healthcare

A Magnetic Particle Imaging scanner will be installed in The F.M. Kirby Imaging Center at Kennedy Krieger Institute in Baltimore, Maryland.

It is estimated that nearly 5 million people visit the emergency room each year for a suspected concussion. However, about half of all concussions go undetected with current standard-of-care analysis, including CT scans.

Study will evaluate outcomes from integrating oral health care with community health center services

Philadelphia, PA – Oncoceutics, Inc., announced that it has signed an exclusive, world-wide license for US patent #10,239,877, entitled “Pharmacophore for trail induction”, from The Scripps Research Institute, covering the composition of matter of ONC201 as well as other molecules in the imipridone family.

Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.

The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

An article published in Experimental Biology and Medicine describes a new class of kinase inhibitors.

There are numerous ongoing projects between healthcare institutions and biopharmaceutical companies that are focusing on deep dives into patients’ genes, hoping to provide insights that can lead to newer, better drugs developed faster. But they’re not without their controversies.

The shortage isn’t new, although it appears to be hitting more of a crisis point.

Sareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019.